Cochrane · systematic review · CD000053
Drugs for treating urinary schistosomiasis
Kramer, CV, Zhang, F, Sinclair, D, et al. · Cochrane Database of Systematic Reviews · 2014 · Cochrane Library
Infectious DiseasesAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
30
current version
GRADE rated
29
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 1 · 3.3%Very low 10 · 33.3%Low 13 · 43.3%Moderate 4 · 13.3%High 2 · 6.7%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Praziquantel 40 mg/kg versus placebo for treating urinary schistosomiasis
Population: People with urinary schistosomiasis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Parasitological failure At 1 to 2 months Praziquantel 40 mg/kg vs placebo | RR 0.42 [0.29, 0.59] | 7 studies · 864 participants | High |
Percentage egg reduction At 1 to 2 months Praziquantel 40 mg/kg vs placebo | no estimate extracted | 6 studies · 678 participants | High |
Microhaematuria At 8 weeks Praziquantel 40 mg/kg vs placebo | RR 0.53 [0.33, 0.84] | 1 study · 119 participants | Low Downgraded: risk of bias, imprecision, indirectness |
Haemoglobin At 6 to 8 months Praziquantel 40 mg/kg vs placebo | no estimate extracted | 2 studies · 727 participants | Moderate Downgraded: risk of bias, imprecision, inconsistency, indirectness |
Adverse events Praziquantel 40 mg/kg vs placebo | no estimate extracted | 9 studies · 1591 participants | Low Downgraded: risk of bias |
Praziquantel 40 mg/kg single dose versus 30 mg/kg single dose
Population: people with urinary schistosomiasis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Parasitological failure At 1 month Praziquantel 40 mg/kg single dose vs 30 mg/kg single dose | RR 0.76 [0.59, 0.99] | 4 studies · 401 participants | Low Downgraded: risk of bias, imprecision, inconsistency, indirectness |
Mean percent egg reduction At 1 month Praziquantel 40 mg/kg single dose vs 30 mg/kg single dose | no estimate extracted | 4 studies · 362 participants | Low Downgraded: risk of bias, imprecision, inconsistency, indirectness |
Parasitological failure At 6 months Praziquantel 40 mg/kg single dose vs 30 mg/kg single dose | RR 0.97 [0.76, 1.23] | 6 studies · 669 participants | Moderate Downgraded: risk of bias, imprecision, inconsistency, indirectness |
Mean percent egg reduction At 6 months Praziquantel 40 mg/kg single dose vs 30 mg/kg single dose | no estimate extracted | 4 studies · 362 participants | Low Downgraded: risk of bias, inconsistency, indirectness |
Haematuria Praziquantel 40 mg/kg single dose vs 30 mg/kg single dose | RR 0.89 [0.47, 1.67] | 1 study · 117 participants | Very low Downgraded: risk of bias, imprecision, indirectness |
Proteinuria Praziquantel 40 mg/kg single dose vs 30 mg/kg single dose | RR 0.85 [0.34, 2.12] | 1 study · 117 participants | Very low Downgraded: risk of bias, imprecision, indirectness |
Adverse events Praziquantel 40 mg/kg single dose vs 30 mg/kg single dose | no estimate extracted | 8 studies · 992 participants | Low Downgraded: risk of bias |
Praziquantel 40 mg/kg multiple doses versus single dose
Population: patients with treating urinary schistosomiasis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Parasitological failure At 2 years Praziquantel 40 mg/kg multiple doses vs single dose | RR 2.71 [1.47, 5] | 1 study · 62 participants | Very low Downgraded: risk of bias, imprecision, inconsistency, indirectness |
Mean percent egg reduction At 2 years Praziquantel 40 mg/kg multiple doses vs single dose | no estimate extracted | 1 study · 62 participants | Very low Downgraded: risk of bias, imprecision, inconsistency, indirectness |
Parasitological failure At 3 years Praziquantel 40 mg/kg multiple doses vs single dose | RR 0.92 [0.59, 1.42] | 1 study · 43 participants | Very low Downgraded: risk of bias, imprecision, inconsistency, indirectness |
Haematuria At 3 years Praziquantel 40 mg/kg multiple doses vs single dose | RR 0.7 [0.42, 1.17] | 1 study · 43 participants | Very low Downgraded: risk of bias, imprecision, inconsistency, indirectness |
Adverse events Praziquantel 40 mg/kg multiple doses vs single dose | no estimate extracted | 1 study · 43 participants | Very low |
Metrifonate 3 x 7.5 mg/kg given two weeks apart versus placebo
Population: patients with treating urinary schistosomiasis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Parasitological failure At 2 to 2.5 months Metrifonate 3 x 7.5 mg/kg given two weeks apart vs placebo | RR 0.41 [0.3, 0.56] | 1 study · 93 participants | Low Downgraded: risk of bias, inconsistency |
Mean percent egg reduction At 2 to 2.5 months Metrifonate 3 x 7.5 mg/kg given two weeks apart vs placebo | no estimate extracted | 1 study · 93 participants | Low Downgraded: risk of bias, inconsistency |
Parasitological failure At 6 months Metrifonate 3 x 7.5 mg/kg given two weeks apart vs placebo | RR 0.3 [0.24, 0.37] | 1 study · 400 participants | Moderate Downgraded: inconsistency |
Mean percent egg reduction At 6 months Metrifonate 3 x 7.5 mg/kg given two weeks apart vs placebo | no estimate extracted | 1 study · 400 participants | Moderate Downgraded: inconsistency |
Adverse events Metrifonate 3 x 7.5 mg/kg given two weeks apart vs placebo | no estimate extracted | 2 studies · 493 participants | Ungraded |
Artesunate versus placebo
Population: patients with treating urinary schistosomiasis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Parasitological failure At 8 weeks Artesunate vs placebo | RR 0.53 [0.16, 1.71] | 2 studies · 251 participants | Very low Downgraded: risk of bias |
Mean percent egg reduction At 8 weeks Artesunate vs placebo | no estimate extracted | 2 studies · 276 participants | Low Downgraded: risk of bias |
Microhaematuria At 8 weeks Artesunate vs placebo | RR 1.22 [0.85, 1.76] | 1 study · 119 participants | Low Downgraded: risk of bias, imprecision, inconsistency, indirectness |
Adverse events Artesunate vs placebo | no estimate extracted | 2 studies · 276 participants | Low Downgraded: risk of bias, imprecision, inconsistency, indirectness |
Praziquantel and artesunate versus praziquantel
Population: patients with urinary schistosomiasis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Parasitological failure at 8 weeks Praziquantel and artesunate vs praziquantel | RR 0.62 [0.38, 0.99] | 2 studies · 265 participants | Low Downgraded: risk of bias, imprecision, inconsistency, indirectness |
Percent egg reduction Praziquantel and artesunate vs praziquantel | no estimate extracted | 2 studies · 265 participants | Very low Downgraded: risk of bias, imprecision, inconsistency |
Microhaematuria Praziquantel and artesunate vs praziquantel | RR 0.69 [0.4, 1.18] | 1 study · 177 participants | Low Downgraded: risk of bias, imprecision |
Adverse events Praziquantel and artesunate vs praziquantel | no estimate extracted | 1 study · 156 participants | Very low Downgraded: risk of bias, imprecision |